Fractyl Health, Inc. (GUTS) announced FDA approval of a pivotal Investigational Device Exemption to study Revita's efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist drug therapy. The IDE approval launches the Remain-1 study, set to begin in the second half of 2024.
Revita is an outpatient endoscopic procedure that targets the duodenum and is designed to reverse pathology in the duodenal lining that is a root cause of obesity and T2D. Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.